BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS

After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses. After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources…

Source: FierceBiotech